A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV.

PrEP plays a key part in reducing the number of new HIV infections by stopping the virus talking hold in the body and replicating.

While the most common PrEP therapies are highly effective at shielding people from HIV, the pills need to be taken once a day to maintain protection.

Current "long-acting" PrEP therapies, meanwhile, require injection by a healthcare provider typically every couple of months, which isn't always feasible.

Hence, a pill that only needs to be taken monthly could improve accessibility, adherence, privacy and reduce concerns about stigma.

In 2024, 1.3 million people were newly infected with HIV, a figure that has reduced by 61 percent since the peak in 1

See Full Page